Skip to the page

Data / Federal grants / RFA-CA-27-001

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

National Institutes of Health (Department of Health and Human Services) is accepting applications until November 10, 2026. It lists awards of up to $150,000, 20 awards expected, $5.1 million in total.

SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.

Key facts

Opportunity number
RFA-CA-27-001
Status
Posted, open
Posted
June 3, 2026
Closes
November 10, 2026
Award ceiling
$150,000
Expected awards
20
Total funding
$5,100,000
Cost sharing
Not required
Funding instrument
Grant
Category
Health
Assistance listing
93.394 Cancer Detection and Diagnosis Research
Contact
National Institutes of Health · [email protected] · 301-402-2541

Who can apply

  • Public and State controlled institutions of higher education
  • Private institutions of higher education
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • State governments
  • County governments
  • City or township governments
  • For profit organizations other than small businesses
  • Small businesses
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Independent school districts
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Special district governments
  • Native American tribal governments (Federally recognized)
  • Public housing authorities/Indian housing authorities

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

What the agency says

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

The notice on Grants.gov

Other open grants from the Department of Health and Human Services

All grants open to Public colleges and universities · All grants open to Private colleges and universities · All grants open to Nonprofits without 501(c)(3) status · Everything closing in November 2026

Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.